Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

324
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
324
Asthma-I: Introduction01:29

Asthma-I: Introduction

2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

2.4K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
2.4K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

222
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
222

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

An early window into immune developmental trajectory of asthma.

American journal of respiratory and critical care medicine·2026
Same author

Stability and age-specific patterns of rhinovirus circulation in children observed over 3 decades.

The Journal of allergy and clinical immunology·2026
Same author

Single cell transcriptional profiling of monocytes from asthma patients show a predisposition for an inflammatory response.

Cytotherapy·2025
Same author

Child Opportunity Index and Outcomes of Children Admitted to US PICUs for Critical Asthma.

Pediatric pulmonology·2025
Same author

Phenotype-Based Management of Recurrent Preschool Wheezing and Asthma.

The journal of allergy and clinical immunology. In practice·2025
Same author

Single-cell RNA-sequencing of circulating eosinophils from asthma patients reveals an inflammatory signature.

iScience·2025

相关实验视频

Updated: May 25, 2025

Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

40.1K

喘的表型和生物标志物

Jocelyn R Grunwell1, Anne M Fitzpatrick2

  • 1Dr. Grunwell is affiliated with Division of Critical Care Medicine, Department of Pediatrics, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia.

Respiratory care
|February 27, 2025
PubMed
概括

通过2型高和2型低的炎症表型,更好地了解严重的喘异质性. 生物标志物评估指导了针对成人和儿童重症喘治疗的生物选择.

关键词:
过敏敏感化过敏敏感化喘 喘 是一种生物标志物生物标志物集群集群是一个集群集群.终极类型 终极类型 终极类型恶化的恶化.隐性类分析 隐性类分析现象型 现象型 是一种现象型.这是一种2型炎症.

更多相关视频

Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

27.4K
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

22.3K

相关实验视频

Last Updated: May 25, 2025

Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

40.1K
Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

27.4K
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

22.3K

科学领域:

  • 免疫学和肺病学.
  • 翻译医学是一种翻译医学.
  • 临床的表型化 临床的表型化

背景情况:

  • 喘在成人和儿童中呈现不同的表型,严重的病例表现出持续的症状,尽管治疗.
  • 研究重点是严重的喘异质性,导致识别2型高和2型低的炎症概况.
  • 2型高喘涉及特定的免疫路径和eosinophilic炎症,而2型低喘是不太了解和耐皮质类固醇.

研究的目的:

  • 审查成人和儿科喘表型的病理生物学.
  • 讨论严重喘的基于表型的治疗策略,包括生物疗法.
  • 探索临床表型,以指导门诊管理,并确定潜在的高风险儿科表型.

主要方法:

  • 审查有关喘病理生物学,表型和治疗的现有文献.
  • 对分类方法的分析,包括监督和无监督方法.
  • 对生物标志物面板的评估,以指导严重喘中的生物选择.

主要成果:

  • 严重的喘根据炎症标志物被分为2型高和2型低的表型.
  • 针对2型高炎症的生物药物在减少恶化方面表现有前途.
  • 生物标记面板 (血液中乙氨基基,IgE,FeNO) 有助于选择适当的生物疗法.

结论:

  • 了解喘表型对于个性化治疗策略至关重要.
  • 生物疗法为严重喘提供了有针对性的选择,特别是2型喘.
  • 需要进一步的研究来充分描述2型低喘,并确定高风险的儿科表型,包括需要接受ICU治疗的儿童.